Advertisement
Screener

CERO THERAPEUTICS HOLDINGS, INC. (CERO) Increase (Decrease) in Derivative Liabilities

2.8 / 5 stars · 68/120 Roast Me

CERO THERAPEUTICS HOLDINGS, INC. Increase (Decrease) in Derivative Liabilities

CERO THERAPEUTICS HOLDINGS, INC. (CERO) reported Increase (Decrease) in Derivative Liabilities of $320.12 thousand for the 1-month period ending 2024-02-13, per its 10-K filed 2026-04-15.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInDerivativeLiabilities · last filed 2026-04-15

  • 2024-02-13: Increase (Decrease) in Derivative Liabilities 1 month $320.12K.
Period endIncrease (Decrease) in Derivative Liabilities 1 month
2024-02-13$320.12K
10-K · filed 2026-04-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)United States$0.006B
AIM ImmunoTech Inc. (AIM)United States$0.006B
TScan Therapeutics, Inc. (TCRX)United States$0.008B-1.23
PharmaCyte Biotech, Inc. (PMCB)United States$0.005B
WINDTREE THERAPEUTICS INC /DE/ (WINT)United States$0.003B-0.32
VivoSim Labs, INC. (VIVS)United States$0.003B
Senti Biosciences Holdings, Inc. (SNTI)United States$0.011B-0.70
Calidi Biotherapeutics, Inc. (CLDI)United States$0.003B
IN8BIO, INC. (INAB)United States$0.012B-0.76
CURIS INC (CRIS)United States$0.002B-0.05